RecruitingPhase 1Phase 2NCT01898663

DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML

Safety and Therapeutic Efficacy of DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML: a Phase Ⅰ/Ⅱ Study


Sponsor

Affiliated Hospital to Academy of Military Medical Sciences

Enrollment

30 participants

Start Date

Jun 1, 2013

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of this Phase Ⅰ/Ⅱ study is to evaluate the safety and efficacy of dendritic cells (DCs) vaccine combined with cytokine-induced killer (CIK) cells in patients with AML. Experimental recombinant adenovirus-transfected DCs, which engineered to express MUC1 and Survivin are used for DCs-based immunotherapy. Based on the results of our previously performed preclinical study with DCs vaccine combined with CIK cells, the investigators plan to perform the clinical trial.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether combining a special immune cell vaccine (made from a patient's own immune cells) with another type of immune cell therapy can help the body fight advanced cancer more effectively. **You may be eligible if...** - You have been diagnosed with an advanced or metastatic cancer that has not responded well to standard treatments - You are well enough to carry out everyday activities - Your major organs (heart, liver, kidneys) are functioning adequately - You have not received certain immune-suppressing medications recently **You may NOT be eligible if...** - You have a serious autoimmune disease - You are pregnant or breastfeeding - You have active infections, including HIV or hepatitis - You have had a recent major surgery or severe illness - You are currently taking medications that significantly suppress the immune system - You have brain metastases that are unstable or untreated Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALAdenovirus-transfected DC + CIK

Adenovirus-transfected autologous DC vaccine plus CIK cells


Locations(1)

Department of Hematopoietic Stem Cell Transplantation

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT01898663